Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
Connect Biopharma Holdings Limited announced that the independent Data Monitoring Committee has completed its interim analysis of the Phase 2 Seabreeze STAT studies investigating rademikibart for acute exacerbations of asthma and COPD. The interim results showed no safety concerns and no recommendation to change sample sizes, allowing enrollment to…